Sitagliptin, a DPP-4 Inhibitor, Acutely Inhibits Intestinal Lipoprotein Particle Secretion in Healthy Humans
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sitagliptin, a DPP-4 Inhibitor, Acutely Inhibits Intestinal Lipoprotein Particle Secretion in Healthy Humans
Authors
Keywords
-
Journal
DIABETES
Volume 63, Issue 7, Pages 2394-2401
Publisher
American Diabetes Association
Online
2014-03-01
DOI
10.2337/db13-1654
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel Role of Enteral Monosaccharides in Intestinal Lipoprotein Production in Healthy Humans
- (2013) Changting Xiao et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans
- (2012) Changting Xiao et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- GLP-1 and GLP-2 as Yin and Yang of Intestinal Lipoprotein Production: Evidence for Predominance of GLP-2-Stimulated Postprandial Lipemia in Normal and Insulin-Resistant States
- (2012) G. J. Hein et al. DIABETES
- The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with Type 2 diabetes
- (2012) N. Matikainen et al. DIABETIC MEDICINE
- Cardiovascular Biology of the Incretin System
- (2012) John R. Ussher et al. ENDOCRINE REVIEWS
- Gut-liver interaction in triglyceride-rich lipoprotein metabolism
- (2011) Changting Xiao et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes
- (2011) A. J. Tremblay et al. DIABETES OBESITY & METABOLISM
- Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus
- (2010) Eric A. Schwartz et al. ATHEROSCLEROSIS
- Effects of Acute Hyperglucagonemia on Hepatic and Intestinal Lipoprotein Production and Clearance in Healthy Humans
- (2010) C. Xiao et al. DIABETES
- DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
- (2010) J. B. Buse et al. DIABETES CARE
- Incretin Therapies: Effects Beyond Glycemic Control
- (2009) Sunder Mudaliar et al. AMERICAN JOURNAL OF MEDICINE
- Insulin Acutely Inhibits Intestinal Lipoprotein Secretion in Humans in Part by Suppressing Plasma Free Fatty Acids
- (2009) M. Pavlic et al. DIABETES
- The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
- (2009) J. Hsieh et al. DIABETOLOGIA
- Incretin-based therapies for type 2 diabetes mellitus
- (2009) Julie A. Lovshin et al. Nature Reviews Endocrinology
- Both Intestinal and Hepatic Lipoprotein Production Are Stimulated by an Acute Elevation of Plasma Free Fatty Acids in Humans
- (2008) Hélène Duez et al. CIRCULATION
- Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
- (2008) Ralph A. DeFronzo et al. CURRENT MEDICAL RESEARCH AND OPINION
- Intestinal lipoprotein overproduction in insulin-resistant states
- (2008) Khosrow Adeli et al. CURRENT OPINION IN LIPIDOLOGY
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation